Page last updated: 2024-10-27

gabapentin and Benign Neoplasms, Brain

gabapentin has been researched along with Benign Neoplasms, Brain in 10 studies

Gabapentin: A cyclohexane-gamma-aminobutyric acid derivative that is used for the treatment of PARTIAL SEIZURES; NEURALGIA; and RESTLESS LEGS SYNDROME.
gabapentin : A gamma-amino acid that is cyclohexane substituted at position 1 by aminomethyl and carboxymethyl groups. Used for treatment of neuropathic pain and restless legs syndrome.

Research Excerpts

ExcerptRelevanceReference
"Seizures associated with intracranial neoplasms are occasionally refractory to conventional anti-epileptic drugs."5.29Add-on gabapentin for refractory seizures in patients with brain tumours. ( Perry, JR; Sawka, C, 1996)
"Patients undergoing craniotomy received either placebo (group D) or gabapentin (600 mg) (group GD) premedication orally, 2 hours before induction of anesthesia."5.17The effect of gabapentin premedication on postoperative nausea, vomiting, and pain in patients on preoperative dexamethasone undergoing craniotomy for intracranial tumors. ( Misra, S; Parthasarathi, G; Vilanilam, GC, 2013)
"Therefore, the optimal seizure management by antiepileptic drugs (AEDs) in this patient category is essentially unsure."2.43Optimal seizure management in brain tumor patients. ( van Breemen, MS; Vecht, CJ, 2005)
"Seizures associated with intracranial neoplasms are occasionally refractory to conventional anti-epileptic drugs."1.29Add-on gabapentin for refractory seizures in patients with brain tumours. ( Perry, JR; Sawka, C, 1996)

Research

Studies (10)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (10.00)18.2507
2000's3 (30.00)29.6817
2010's5 (50.00)24.3611
2020's1 (10.00)2.80

Authors

AuthorsStudies
Krishna, S1
Choudhury, A1
Keough, MB1
Seo, K1
Ni, L1
Kakaizada, S1
Lee, A1
Aabedi, A1
Popova, G1
Lipkin, B1
Cao, C1
Nava Gonzales, C1
Sudharshan, R1
Egladyous, A1
Almeida, N1
Zhang, Y1
Molinaro, AM1
Venkatesh, HS1
Daniel, AGS1
Shamardani, K1
Hyer, J1
Chang, EF1
Findlay, A1
Phillips, JJ1
Nagarajan, S1
Raleigh, DR1
Brang, D1
Monje, M1
Hervey-Jumper, SL1
Corona-Ramos, JN1
Déciga-Campos, M1
Romero-Piña, M1
Medina, LA1
Martínez-Racine, I1
Jaramillo-Morales, OA1
García-López, P1
López-Muñoz, FJ1
Laghari, AA1
Ahmed, SI1
Qadeer, N1
Shamim, MS1
Mari, Z1
Rosenthal, LS1
Darwin, KC1
Hallett, M1
Jinnah, HA1
Misra, S2
Parthasarathi, G1
Vilanilam, GC1
Crespo Pérez, L1
Moreira Vicente, V1
Cano Ruiz, A1
Gobernado Serrano, JM1
Cobo Ibañez, N1
Milicua Salamero, JM1
Koshy, T1
Unnikrishnan, KP1
Suneel, PR1
Chatterjee, N1
Porzio, G1
Aielli, F1
Narducci, F1
Varrassi, G1
Ricevuto, E1
Ficorella, C1
Marchetti, P1
van Breemen, MS1
Vecht, CJ1
Perry, JR1
Sawka, C1

Clinical Trials (1)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Gabapentin Regimens and Their Effects on Opioid Consumption[NCT03334903]Phase 477 participants (Actual)Interventional2018-05-15Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

"VAS Score 1: How Much Pain do You Feel in Your Operative Site When Resting?"

Surgical site pain. Scale 0-10, with 0 best and 10 worst (NCT03334903)
Timeframe: 2-3 months after surgery (at 2nd postoperative appointment)

Interventionscore on 10-point scale (Mean)
Standard of Care2.26
Postoperative Gabapentin Regimen2.46

"VAS Score 2: How Much Pain do You Feel in Your Operative Site When Moving?"

Surgical site pain. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care3.84
Postoperative Gabapentin Regimen3.54

"VAS Score 3: How Well Are You Sleeping?"

Sleep quality. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care5.73
Postoperative Gabapentin Regimen6.38

"VAS Score 4: How Bad is Your Nausea?"

Nausea. Scale 0-10, with 0 best and 10 worst. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care0.36
Postoperative Gabapentin Regimen0.17

"VAS Score 5: How Satisfied Are You With Your Pain Management?"

Satisfaction. Scale 0-10 with 0 worst and 10 best. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventionscore on a 10-point scale (Mean)
Standard of Care7.83
Postoperative Gabapentin Regimen8.48

Days Taking Opioids

Number of days until patients are finished consuming opioid medications after discharge. (NCT03334903)
Timeframe: 2-3 months following surgery (measured at second postoperative appointment).

Interventiondays (Mean)
Standard of Care14.8
Postoperative Gabapentin Regimen18.7

Opioid Consumption

Mean opioid consumption, measured in mg of morphine equivalents. (NCT03334903)
Timeframe: 2-3 months following surgery (total amount measured at second postoperative appointment; means assessed afterwards).

Interventionmorphine equivalents (Mean)
Standard of Care287.0
Postoperative Gabapentin Regimen281.1

Reviews

4 reviews available for gabapentin and Benign Neoplasms, Brain

ArticleYear
Choice of therapeutic anti-seizure medication in patients with brain tumour.
    JPMA. The Journal of the Pakistan Medical Association, 2019, Volume: 69, Issue:3

    Topics: Anticonvulsants; Brain Neoplasms; Drug Therapy, Combination; Epilepsy; Gabapentin; Glioma; Humans; L

2019
Clinical Reasoning: a 57-year-old man with jaw spasms.
    Neurology, 2013, Mar-05, Volume: 80, Issue:10

    Topics: Adrenergic Uptake Inhibitors; Amines; Anticonvulsants; Brain Neoplasms; Cyclohexanecarboxylic Acids;

2013
[Anticonvulsant hypersensitivity syndrome: an entity to be remembered].
    Gastroenterologia y hepatologia, 2009, Volume: 32, Issue:10

    Topics: Adolescent; Amines; Anemia, Hemolytic; Anticonvulsants; Astrocytoma; Brain Neoplasms; Carbamazepine;

2009
Optimal seizure management in brain tumor patients.
    Current neurology and neuroscience reports, 2005, Volume: 5, Issue:3

    Topics: Amines; Anticonvulsants; Antineoplastic Agents; Brain Neoplasms; Cyclohexanecarboxylic Acids; Drug I

2005

Trials

2 trials available for gabapentin and Benign Neoplasms, Brain

ArticleYear
The effect of gabapentin premedication on postoperative nausea, vomiting, and pain in patients on preoperative dexamethasone undergoing craniotomy for intracranial tumors.
    Journal of neurosurgical anesthesiology, 2013, Volume: 25, Issue:4

    Topics: Adult; Amines; Anesthesia; Anti-Inflammatory Agents; Brain Neoplasms; Craniotomy; Cyclohexanecarboxy

2013
Gabapentin premedication decreases the hemodynamic response to skull pin insertion in patients undergoing craniotomy.
    Journal of neurosurgical anesthesiology, 2011, Volume: 23, Issue:2

    Topics: Adolescent; Adult; Amines; Anesthesia, General; Anesthetics, Inhalation; Anesthetics, Local; Blood P

2011

Other Studies

4 other studies available for gabapentin and Benign Neoplasms, Brain

ArticleYear
Glioblastoma remodelling of human neural circuits decreases survival.
    Nature, 2023, Volume: 617, Issue:7961

    Topics: Biopsy; Brain; Brain Neoplasms; Cell Proliferation; Cognition; Disease Progression; Gabapentin; Glio

2023
The Effect of Gabapentin and Tramadol in Cancer Pain Induced by Glioma Cell in Rat Femur.
    Drug development research, 2017, Volume: 78, Issue:5

    Topics: Amines; Analgesics; Animals; Bone Neoplasms; Brain Neoplasms; Cancer Pain; Cell Line, Tumor; Cell Su

2017
Hiccup in patients with advanced cancer successfully treated with gabapentin: report of three cases.
    The New Zealand medical journal, 2003, Sep-26, Volume: 116, Issue:1182

    Topics: Acetates; Adult; Amines; Anticonvulsants; Brain Neoplasms; Carcinoma, Small Cell; Colonic Neoplasms;

2003
Add-on gabapentin for refractory seizures in patients with brain tumours.
    The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1996, Volume: 23, Issue:2

    Topics: Acetates; Amines; Anticonvulsants; Brain Neoplasms; Cyclohexanecarboxylic Acids; Follow-Up Studies;

1996